Found: 12
Select item for more details and to access through your institution.
263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 2, p. 327, doi. 10.1007/s13555-018-0234-5
- By:
- Publication type:
- Article
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 1, p. 57, doi. 10.1007/s13555-018-0220-y
- By:
- Publication type:
- Article
Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses <i>In Vitro</i>.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0086322
- By:
- Publication type:
- Article
Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains.
- Published in:
- Immunological Reviews, 2002, v. 189, n. 1, p. 136, doi. 10.1034/j.1600-065X.2002.18912.x
- By:
- Publication type:
- Article
Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization.
- Published in:
- Nature Immunology, 2004, v. 5, n. 9, p. 909, doi. 10.1038/ni1108
- By:
- Publication type:
- Article
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.
- Published in:
- Frontiers in Immunology, 2017, v. 8, p. 1, doi. 10.3389/fimmu.2017.00500
- By:
- Publication type:
- Article
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
- Published in:
- AAPS Journal, 2022, v. 24, n. 3, p. 1, doi. 10.1208/s12248-022-00712-2
- By:
- Publication type:
- Article
Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0186046
- By:
- Publication type:
- Article
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
- Published in:
- Immunity, Inflammation & Disease, 2017, v. 5, n. 4, p. 400, doi. 10.1002/iid3.167
- By:
- Publication type:
- Article